Physician profile
Steven Eugene Miller
NPI 1134165905
$7,284.34
in general payments reported to CMS, 2019-2025
43 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $455 · 2021: $634 · 2022: $2,016 · 2023: $1,462 · 2024: $651 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,615 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.37 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,438.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,016.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $840.55 | 2019-2025 | |
| Amgen INC. | $442.05 | 2019-2025 | Evenity, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $389.35 | 2019-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $353.48 | 2019-2023 | Arexvy |
| Lilly USA, LLC | $353.04 | 2019-2023 | Mounjaro |
| Pfizer INC. | $277.89 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $241.90 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.02 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $191.08 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $164.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $145.19 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.21 | 2022-2023 | |
| Astellas Pharma US INC | $93.33 | 2019-2025 | Veozah |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.